| INTRODUCTION
Allergen immunotherapy (AIT), as a causal treatment for IgEmediated allergic diseases, such as rhinoconjunctivitis, allergic asthma, venom allergy, and in some regions atopic dermatitis, has a history of more than a century. In the course of its developing process, details on AIT practice have evolved differently in various parts of the globe, with a striking difference in the practice of AIT, especially subcutaneous AIT (SCIT), between the American and European continent, 1,2 both with their supporting evidence. With the growing number of physicians administering AIT, subcutaneous and lately also sublingually (SLIT), several national and regional allergy societies have tried to give some guidance on the practice of AIT since the 1980s. 3 Depending on the local regulatory situation and extract availability, in some regions the American school and in others the European school of the practice of AIT have been found to be more suitable. However, in general, AIT is still severely underused. In 2009, the first World Allergy Organization (WAO) consensus was published on SLIT, 4 but no such global consensus document for SCIT exists till now. Several AIT guidelines exist at national level; however, some have a more solid evidence-base than others.
With the ever-growing number of guidelines in any medical field being developed over the past decades, in 2010 methodologists from the McMaster University in Hamilton (Ontario, Canada) developed AGREE II (Appraisal of Guidelines for Research & Evaluation II 5, 6 ) a comprehensive tool to evaluate guideline quality, in the broadest sense of the word. The primary goal of a guideline is improving the quality of care in a certain area. As such, the quality of a guideline should be evaluated at population level, rather than at the individual physician's level. Consequently, a guideline should be considered of high quality if it gives adequate evidence-based guidance on how to manage a particular medical condition, but also if it has an adequate strategy of how to be disseminated and applied. The AGREE II guidelines' appraisal tool encompasses all this and evaluates guidelines in 6 domains: (1) Scope and purpose; (2) Stakeholder involvement; (3) Rigor of development; (4) Clarity of presentation,
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Applicability, and (6) Editorial Independence. At the end, the AGREE II tool asks the reviewer to rate the overall quality of the guideline and to state whether the guideline would be recommendable for local use. The first guideline in the allergy world adhering to the AGREE II principals and following the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system for evidence evaluation was the Allergic Rhinitis and its impact on Asthma (ARIA) 2010 update, which includes a complete evaluation at that time-point of the evidence on AIT for allergic rhinitis and for asthma. 7 In this article, we aim to evaluate guidelines specifically focused on allergen immunotherapy (AIT-GLs) with AGREE-II, to distinguish between AIT-GLs with a higher and a lower AGREE II quality score.
This leads us to suggest which AIT-GLs might be best to adhere to, or might be most suitable for local adaptation in countries where no high-quality, evidence-based AIT guidelines exist. Finally, our study also shows in which domains existing AIT guidelines still flaw and could be improved in the future. 
| RESULTS
We found 31 publications of AIT-GLs, see Table 1 . Some specific comments of the reviewers on the guidelines can be found in Table S1 (see the online supporting information tab for this article). | 667
T A B L E 1 Guidelines and consensus papers included in this review

| DISCUSSION
The guidelines-quality assessment tool AGREE II was published in 2010, and the first guideline in the field of allergic diseases published shortly thereafter was the ARIA 2010 revision. When assessed using the AGREE II method, ARIA 2010 was found to rank high for all items, which did not hold true for several other guidelines on allergic rhinitis. 40 The here presented quality evaluation according to AGREE II for AIT-GLs from before and after this publication shows that in general, AIT-GL quality has improved since 2010. Echoing the universal development of GL making, from consensus documents in the 1970-1980s, through pure evidence-based-medicine in the 1990s, to the more comprehensive GRADE approach from the past decade. In GRADE, a balance is sought between the 4 pillars on which recommendations and suggestions for medical treatment are based (evidence, patient preference, cost, and safety). AIT-GLs have had a similar evolution since the first document in 1988. 3 Even so, certain domains are still sensitive to improvement. This holds especially true for the domains (2) Stakeholder involvement,
Rigor of Development, and (5) Applicability. guidelines (the German 38 and the Mexican 28 ) made an attempt to follow this GRADE approach and consequently scored higher in domain 3. Many other guidelines still followed the Shekelle system, thus obtaining a suboptimal score for domain 3. Therefore, there has only been a slight improvement in this domain, comparing older vs newer AIT-GLs (P < .05).
Concerning the low scoring domains 2 and 5, these are closely linked to dissemination and implementation of a GL. Domain 5 (applicability) seems the most interesting domain, as here the pre-2010
AIT-GLs scored better than the newer ones. A possible explanation for this finding might be that older GLs were more focused on informing clinical assistants on how to treat allergic diseases, while newer GLs might be focusing more on improving knowledge, reducing the focus on dissemination.
It is generally accepted that AIT is still underused, 41 State in the first section of the document the detailed scope of the GL (which patients, which disease, which interventions) and the purpose of the GL. Domain 2. Stakeholder involvement Into the guideline development group one should invite experts, related expert groups (eg, ENT, pulmonologists), primary care physicians, patients, and others that might be involved in GL implementation (eg, representatives of governmental/administrative bodies, pharmaceutical industry) and methodologists. Involve them early-on in the process. A core group of only a few that prepares the initial lay-out and drafts might be a solution, to avoid slowing the process when the GDG becomes too big. But an initial, mid-, and final face-to-face meeting with the whole group is recommendable. Domain 3. Rigor of Development For original GLs: structured literature search, selection and analysis of articles, fusion of evidence and how recommendations are developed based on evidence, safety, cost, patient preference.
(eg, GRADE approach, SIGN) For transculturized GLs: see ADAPTE approach, all evidence comes from the selected "mother" GL(s). Domain 4. Clarity of presentation Bullet-point presentation at the beginning/end of the document on the recommendations and suggestions, so they can easily be found by readers without going through the whole document.
Domain 5. Applicability
Discuss with the whole GDG barriers and obstacles for GL implementation, and how to solve them. Facilitate GL implementation with user-friendly (downloadable) application sheets, in which recommended steps are plotted. (eg, US AIT practice parameters' sheets).
Domain 6. Editorial independence
Apply a method (and describe in the GL) to reduce bias from GDG members with conflicts of interest and from the financing body.
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| 669 the applicability of the GL. Paying special attention to improving these domains in future AIT-GLs would be highly desirable, see Table 2 . In the previously mentioned AGREE II evaluation of allergic rhinitis GLs, the same domains 2 and 5 were found to rank low. 40 After analyzing all results, it amazed the investigators to see how little difference there is between older and the newer AIT-GLs in the global mean guideline AGREE-II-quality-scoring. Taking a closer look, we realized that this could partly be due to the fact that within each group of newer vs older AIT-GLs, some GLs are of higher and others are of much lower quality (see Figure 1 ) resembling more consensus documents and thus reducing the mean scoring of the whole guidelines' group. Therefore, in a post hoc analysis, we selected from the 2010-onward GLs only those with a mean score above 40%. Recalculating statistics based on this group of 9 AIT-GLs all domains showed statistically significant improvement vs the older GLs.
Under low-resource conditions (both economically and intellectually, because of time restraint of local experts), it can be very difficult to develop a GL from zero, based on all published literature. In such situations, the ADAPTE tool can be very useful, allowing high-quality existing GLs to be adapted to local reality. 42 In ADAPTE, the literature search is thus for GLs published specifically in the field of interest, which subsequently are analyzed with AGREE II to select the ones with best-quality, most suitable for adaptation. As such, a locally adjusted high-quality GL can be developed without too much investment in the collection and evaluation of evidence. This might leave some resources for inviting more stakeholders and thus enhancing applicability.
The last domain, 6, on editorial independence, though much improved in the newer GLs, still only scores 4/7 points, as often conflict of interests and financing bodies are declared, without describing a method to avoid that these interfere with the GL content.
In this discussion, a word must be said about the tool we used, AGREE II, as well. Although it analyzes guidelines through a structured item list, with clear explanations in a manual on how to apply them, 43 finally it is based on the reviewer's criterion of scoring, a subjective measure. We came across this issue, as most GLs were revised in groups of 2 and on some items discrepancies arose, that in 3 cases continued even after the second round of discussion and re-revision of both reviewers. In these cases, we asked orientation of the methodologists. At that point, it became clear that some items could be sensitive to personal interpretation and thus not be uniformly scored by all reviewers. Here, the group decided to interpret as unanimously as possible and analyze all GLs with the same criterion.
Resuming, Table 2 shows per domain suggestions of the reviewers for developers of future AIT-GLs that might enhance the overall quality and thus implementation. These are only suggestions, as till now no AIT guideline has been subject to validation in the real world, nor can we assure that the best guidelines as described by AGREE II are more able to be used more often and at their best in the real life. But till now, it is the best tool we have.
During the past months, several systematic reviews have been published by a Task Force of the European Academy of Allergy and Clinical Immunology (EAACI) on AIT for allergic rhinitis, 44 allergic asthma, 45 and for allergy prevention, 46 to name some. Authors anticipate these are the preparatory documents for a set of guidelines from the EAACI on the different aspects of AIT. This kind of preparation seems adequate for the development of a high-quality guideline.
The final EAACI guideline documents shall have to be awaited to evaluate them with AGREE II and to confirm or reject this suspicion.
| CONCLUSION S
In AIT-GLs, there is still a lot of room for improvement, especially in 2 domains, crucial in dissemination (stakeholder involvement and applicability). For some, the "Scientific rigor" domain flawed. In situations with limited resources, local adjustment ("transculturizing"), a high-quality AIT-GL might be appropriate and preferable over the development of a low-quality one. The AGREE II instrument could help to pick quality candidate AIT-GLs for such a procedure.
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